2Seventy Bio Valuation
| TSVTDelisted Stock | USD 5.00 0.00 0.00% |
At this time, the firm appears to be overvalued. 2Seventy Bio shows a prevailing Real Value of $3.71 per share. The current price of the firm is $5.0. Our model approximates the value of 2Seventy Bio from analyzing the firm fundamentals such as return on equity of -0.0194, and Profit Margin of (0.08) % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that 2Seventy Bio's price fluctuation is very steady at this time. Calculation of the real value of 2Seventy Bio is based on 3 months time horizon. Increasing 2Seventy Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
2Seventy Bio's intrinsic value may or may not be the same as its current market price of 5.00, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.0 | Real 3.71 | Hype 5.0 | Naive 4.49 |
The intrinsic value of 2Seventy Bio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence 2Seventy Bio's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of 2Seventy Bio helps investors to forecast how 2Seventy stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 2Seventy Bio more accurately as focusing exclusively on 2Seventy Bio's fundamentals will not take into account other important factors: 2Seventy Bio Total Value Analysis
2Seventy Bio is at this time anticipated to have valuation of 335.53 M with market capitalization of 266.14 M, debt of 243.72 M, and cash on hands of 357.93 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the 2Seventy Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
335.53 M | 266.14 M | 243.72 M | 357.93 M |
2Seventy Bio Investor Information
About 82.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.24. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. 2Seventy Bio recorded a loss per share of 0.08. The entity had not issued any dividends in recent years. Based on the analysis of 2Seventy Bio's profitability, liquidity, and operating efficiency, 2Seventy Bio is not in a good financial situation at the moment. It has a very high risk of going through financial straits in February.2Seventy Bio Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. 2Seventy Bio has an asset utilization ratio of 7.9 percent. This implies that the Company is making $0.079 for each dollar of assets. An increasing asset utilization means that 2Seventy Bio is more efficient with each dollar of assets it utilizes for everyday operations.2Seventy Bio Ownership Allocation
2Seventy Bio holds a total of 53.23 Million outstanding shares. The majority of 2Seventy Bio outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 2Seventy Bio to benefit from reduced commissions. Therefore, institutional investors are subject to a different set of regulations than regular investors in 2Seventy Bio. Please pay attention to any change in the institutional holdings of 2Seventy Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.2Seventy Bio Profitability Analysis
The company reported the previous year's revenue of 37.86 M. Net Loss for the year was (57.25 M) with loss before overhead, payroll, taxes, and interest of (13.24 M).About 2Seventy Bio Valuation
The delisted stock valuation mechanism determines 2Seventy Bio's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of 2Seventy Bio based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of 2Seventy Bio. We calculate exposure to 2Seventy Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of 2Seventy Bio's related companies.2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2Seventy Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 437 people.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in 2Seventy Stock
If you are still planning to invest in 2Seventy Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the 2Seventy Bio's history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |